Establishing Prognosis in Heart Failure: A Multimarker Approach

Progress in Cardiovascular Diseases

Volumn 54, Issue 2, 2011, Pages 86-96

  Ketchum, Eric Smith ^a   Levy, Wayne Cecil ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Multivariate model; Prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; VALSARTAN;

ANAMNESIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DEATH; DIAGNOSTIC IMAGING; DISEASE MARKER; HEART FAILURE; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; VALIDATION STUDY;

BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80052149913     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.03.003     Document Type: Article

References (114)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Prioreschi P. A history of medicine 2003, Horatius press, Omaha. 1st ed.
3. Allen L.A., Yager J.E., Funk M.J., et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 2008, 299:2533-2542.
4. Knaus W.A., Harrell F.E., Lynn J., et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995, 122:191-203.
5. Frazier C.G., Alexander K.P., Newby L.K., et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol 2007, 49:1450-1458.
6. Parashar S., Katz R., Smith N.L., et al. Race, gender, and mortality in adults > or =65 years of age with incident heart failure (from the Cardiovascular Health Study). Am J Cardiol 2009, 103:1120-1127.
7. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
8. Rector T.S., Ringwala S.N., Anand I.S. Validation of a risk score for dying within 1 year of an admission for heart failure. J Card Fail 2006, 12:276-280.
9. Roberts C.B., Couper D.J., Chang P.P., et al. Influence of life-course socioeconomic position on incident heart failure in blacks and whites: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2010, 172:717-727.
10. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002.
11. Ingelsson E., Lind L., Arnlov J., et al. Socioeconomic factors as predictors of incident heart failure. J Card Fail 2006, 12:540-545.
12. Alexander M., Grumbach K., Remy L., et al. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J 1999, 137:919-927.
13. Smith G.L., Shlipak M.G., Havranek E.P., et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005, 111:1270-1277.
14. East M.A., Peterson E.D., Shaw L.K., et al. Racial differences in the outcomes of patients with diastolic heart failure. Am Heart J 2004, 148:151-156.
15. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
16. Lee D.S., Massaro J.M., Wang T.J., et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. Hypertension 2007, 50:869-876.
17. Miura K., Dyer A.R., Greenland P., et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: the Chicago Heart Association Detection Project in Industry Study. Hypertension 2001, 38:232-237.
18. Levitan E.B., Yang A.Z., Wolk A., et al. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. Circ Heart Fail 2009, 2:202-208.
19. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43:1439-1444.
20. Kenchaiah S., Pocock S.J., Wang D., et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007, 116:627-636.
21. Fonarow G.C., Srikanthan P., Costanzo M.R., et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007, 153:74-81.
22. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
23. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982, 248:1465-1477.
24. Hershberger R.E., Nauman D., Walker T.L., et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003, 9:180-187.
25. Young J.B., Moen E.K. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant 2000, 19:S49-S57.
26. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
27. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
28. Lindenfeld J., Feldman A.M., Saxon L., et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007, 115:204-212.
29. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010, 363:385-395.
30. Barsheshet A., Goldenberg I., Moss A.J., et al. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J 2011, 32:1622-1630.
31. Wong M., Staszewsky L., Latini R., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004, 43:2022-2027.
32. Cohn J.N., Johnson G.R., Shabetai R., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87:VI5-V16.
33. Agha S.A., Kalogeropoulos A.P., Shih J., et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail 2009, 15:586-592.
34. Enriquez-Sarano M., Avierinos J.F., Messika-Zeitoun D., et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005, 352:875-883.
35. Hung J, Koelling T, Semigran MJ, et al: Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol 1998;82:1301-1303, A10.
36. Damy T., Viallet C., Lairez O., et al. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail 2009, 11:818-824.
37. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998, 32:948-954.
38. Hansen A., Haass M., Zugck C., et al. Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure. J Am Coll Cardiol 2001, 37:1049-1055.
39. Bruch C., Rothenburger M., Gotzmann M., et al. Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment. J Am Soc Echocardiogr 2006, 19:522-528.
40. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112:3738-3744.
41. Paulus W.J., van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 2010, 55:526-537.
42. Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010, 55:283-293.
43. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
44. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
45. Varadarajan P., Pai R.G. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. J Card Fail 2003, 9:107-112.
46. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels 1994, Association TCCotNYH, Little, Brown & Co, Boston. 9th ed.
47. Goldman L., Hashimoto B., Cook E.F., et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981, 64:1227-1234.
48. Zugck C., Kruger C., Durr S., et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy?. Eur Heart J 2000, 21:540-549.
49. Guazzi M., Dickstein K., Vicenzi M., et al. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail 2009, 2:549-555.
50. Hsich E., Gorodeski E.Z., Starling R.C., et al. Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction. Circulation 2009, 119:3189-3197.
51. Weber K.T., Janicki J.S. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985, 55:A22-A31.
52. Mancini D.M., Eisen H., Kussmaul W., et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83:778-786.
53. O'Neill J.O., Young J.B., Pothier C.E., et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005, 111:2313-2318.
54. Mancini D., Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010, 122:173-183.
55. Ponikowski P., Francis D.P., Piepoli M.F., et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001, 103:967-972.
56. Chua T.P., Ponikowski P., Harrington D., et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1997, 29:1585-1590.
57. Lang C.C., Karlin P., Haythe J., et al. Peak cardiac power output, measured noninvasively, is a powerful predictor of outcome in chronic heart failure. Circ Heart Fail 2009, 2:33-38.
58. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
59. Triposkiadis F., Karayannis G., Giamouzis G., et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009, 54:1747-1762.
60. Orso F., Baldasseroni S., Maggioni A.P. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis 2009, 52:38-45.
61. Moore R.K., Groves D.G., Barlow P.E., et al. Heart rate turbulence and death due to cardiac decompensation in patients with chronic heart failure. Eur J Heart Fail 2006, 8:585-590.
62. Jacobson A.F., Senior R., Cerqueira M.D., et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55:2212-2221.
63. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996, 93:1963-1969.
64. Vanderheyden M., Bartunek J., Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004, 6:261-268.
65. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292-299.
66. Doust J.A., Pietrzak E., Dobson A., et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005, 330:625.
67. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004, 44:1328-1333.
68. Verdiani V., Nozzoli C., Bacci F., et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 2005, 7:566-571.
69. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
70. Anand I.S., Latini R., Florea V.G., et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005, 112:1428-1434.
71. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
72. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
73. Huehnergarth K.V., Mozaffarian D., Sullivan M.D., et al. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol 2005, 95:1492-1495.
74. Ommen S.R., Hodge D.O., Rodeheffer R.J., et al. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation 1998, 97:19-22.
75. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107:1991-1997.
76. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003, 42:1933-1940.
77. Horwich T.B., Kalantar-Zadeh K., MacLellan R.W., et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008, 155:883-889.
78. Arques S., Ambrosi P., Gelisse R., et al. Hypoalbuminemia in elderly patients with acute diastolic heart failure. J Am Coll Cardiol 2003, 42:712-716.
79. O'Meara E., Clayton T., McEntegart M.B., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006, 113:986-994.
80. Maggioni A.P., Opasich C., Anand I., et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005, 11:91-98.
81. Tang W.H., Tong W., Jain A., et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008, 51:569-576.
82. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004, 110:149-154.
83. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
84. Klein L., O'Connor C.M., Leimberger J.D., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111:2454-2460.
85. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
86. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
87. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
88. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217-1224.
89. Heidecker B., Kasper E.K., Wittstein I.S., et al. Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation 2008, 118:238-246.
90. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928-935.
91. Steyerberg E.W., Vickers A.J., Cook N.R., et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010, 21:128-138.
92. Aaronson K.D., Schwartz J.S., Chen T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2660-2667.
93. Zugck C., Kruger C., Kell R., et al. Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. Eur J Heart Fail 2001, 3:577-585.
94. Koelling T.M., Joseph S., Aaronson K.D. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004, 23:1414-1422.
95. Gardner R.S., Ozalp F., Murday A.J., et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003, 24:1735-1743.
96. Goda A., Lund L.H., Mancini D.M. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. Am J Cardiol 2010, 105:1439-1444.
97. Parikh M.N., Lund L.H., Goda A., et al. Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients >65 years of age with heart failure. Am J Cardiol 2009, 103:998-1002.
98. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
99. May H.T., Horne B.D., Levy W.C., et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007, 100:697-700.
100. Levy W.C., Mozaffarian D., Linker D.T., et al. Can the Seattle Heart Failure Model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?. J Heart Lung Transplant 2009, 28:231-236.
101. Ketchum E.S., Moorman A.J., Fishbein D.P., et al. Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement. J Heart Lung Transplant 2010, 29:1021-1025.
102. Poole-Wilson P.A., Uretsky B.F., Thygesen K., et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003, 89:42-48.
103. Neuberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002, 144:31-38.
104. Mozaffarian D., Anker S.D., Anand I., et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007, 116:392-398.
105. Levy W.C., Lee K.L., Hellkamp A.S., et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009, 120:835-842.
106. Goldenberg I., Vyas A.K., Hall W.J., et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008, 51:288-296.
107. Lee D.S., Austin P.C., Rouleau J.L., et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003, 290:2581-2587.
108. Fonarow G.C., Adams K.F., Abraham W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
109. Austin P.C., Tu J.V., Lee D.S. Logistic regression had superior performance compared with regression trees for predicting in-hospital mortality in patients hospitalized with heart failure. J Clin Epidemiol 2010, 63:1145-1155.
110. O'Connor C.M., Hasselblad V., Mehta R.H., et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010, 55:872-878.
111. Abraham W.T., Fonarow G.C., Albert N.M., et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008, 52:347-356.
112. Brophy J.M., Dagenais G.R., McSherry F., et al. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004, 116:300-304.
113. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27:65-75.
114. Komajda M., Carson P.E., Hetzel S., et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011, 4:27-35.